At the 2017 ASH annual meeting, investigators presented data on the pharmacodynamic effects of copanlisib in patients with NHL and solid tumors that showed dose-dependent on-target activity with the drug.
Researchers presented data at the 2017 ASH annual meeting about their new personalized MDS prediction model that uses clinical and genomic data to help better guide therapy and improve outcomes compared with other models.
A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia cells without harming non-leukemic blood cells, thereby making it a potential target for new therapies.
Researchers found that high levels of IDO (indoleamine 2, 3 dioxygenase) at diagnosis of AML could also identify those who might benefit most by taking an IDO inhibitor along with their standard therapy.
The OncoArray Consortium, an endeavor involving 550 researchers from 6 continents, identified new target genes that may allow for better definition of the pathways and mechanisms underlying breast cancer susceptibility.
Researchers report on the development of a blood-based assay that could potentially provide an earlier warning of small cell lung cancer relapse by improving diagnostic lead-time compared with CT scan.
Researchers analyzed samples from 1,122 patients with advanced-stage NSCLC and discovered that 92.9% of tumors from harbored multiple changes in cancer-related genes in addition to the EGFR driver mutation.